Valneva: H1 sales almost double

(CercleFinance.com) - Valneva has reported total revenues of 93.
2 million euros for H1 2022, up from 47.5 million euros in H1 2021, with growth of 4.7% in product sales, with other revenues almost quadrupling (+281%).

The company said that it made 3.8 million from the first sales of the Covid-19 vaccine, for which it has received four marketing authorisations (European Union, UK, Bahrain, United Arab Emirates).

Valneva has announced a cash position of 336.2 million euros at 30 June, including 90.5 million euros from Pfizer's recent investment in the company through a share subscription agreement.

For FY 2022, the company expects total sales of 340-360 million euros, including the recent amendment to its advance purchase agreement with the European Commission for the Covid-19 vaccine.


Copyright (c) 2022 CercleFinance.com. All rights reserved.